BRIEF RESEARCH REPORT article
Front. Oncol.
Sec. Hematologic Malignancies
Retrospective Analysis of Sorafenib Combined with Interferon α-1b, Interleukin-2, and Thalidomide as Maintenance Therapy in FLT3-ITD-Positive Acute Myeloid Leukemia
Provisionally accepted
- 1Department of hematology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
- 2Central Laboratory, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
- 3Institute of Cancer Research, Henan Academy of Innovations in Medical Science, Zhengzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective To evaluate the clinical efficacy of maintenance therapy with sorafenib combined with interferon α-1b, interleukin-2, and thalidomide (the ITI regimen) in patients with FLT3-ITD-positive acute myeloid leukemia (AML). Methods 19 FLT3-ITD(+) AML patients were retrospectively analyzed, who received the sorafenib combined with ITI regimen as maintenance therapy after achieving remission at Affiliated Cancer Hospital of Zhengzhou University (January 2014–December 2024). Minimal residual disease (MRD) levels were monitored, and clinical outcomes, including survival duration, were assessed. Results This study included 19 patients (9 males, 10 females) with a median age at diagnosis of 59 years (range: 21–76). The median white blood cell count was 32.25×10⁹/L (range: 0.7– 254×10⁹/L). Among them, 13 patients (68.4%) maintained sustained MRD negativity during sorafenib combined with TI regimen therapy, while 3 patients experienced morphological relapse and 3 had molecular relapse. Median overall survival (mOS) was not reached, with 12-and 24-month OS rates of 100% (19/19) and 94.7% (18/19), respectively. During maintenance therapy with sorafenib combined with ITI, median relapse-free survival (mRFS) was also not reached, with 12-and 24-month RFS rates of 73.7% (14/19) and 57.9% (11/19), respectively. Conclusion The sorafenib combined with ITI regimen is an effective maintenance therapy for FLT3-ITD (+) AML, significantly reducing relapse risk and prolonging survival.
Keywords: Sorafenib, Interferon α-1b, Interleukin-2, Thalidomide, FLT3-ITD, Acute Myeloid Leukemia
Received: 04 Sep 2025; Accepted: 29 Oct 2025.
Copyright: © 2025 Cheng, Mi, Li, Chen and Wei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xudong Wei, xudongwei@zzu.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.